Vaccine Development in the Time of COVID-19: The Relevance of the Risklick AI to Assist in Risk Assessment and Optimize Performance

The 2019 coronavirus (COVID-19) pandemic revealed the urgent need for the acceleration of vaccine development worldwide. Rapid vaccine development poses numerous risks for each category of vaccine technology. By using the Risklick artificial intelligence (AI), we estimated the risks associated with...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Quentin Haas, Nikolay Borisov, David Vicente Alvarez, Sohrab Ferdowsi, Leonhard von Meyenn, Douglas Teodoro, Poorya Amini
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
R
Acceso en línea:https://doaj.org/article/26473ecebba642e8bdcb15543e14aa70
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:26473ecebba642e8bdcb15543e14aa70
record_format dspace
spelling oai:doaj.org-article:26473ecebba642e8bdcb15543e14aa702021-12-01T02:53:16ZVaccine Development in the Time of COVID-19: The Relevance of the Risklick AI to Assist in Risk Assessment and Optimize Performance2673-253X10.3389/fdgth.2021.745674https://doaj.org/article/26473ecebba642e8bdcb15543e14aa702021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fdgth.2021.745674/fullhttps://doaj.org/toc/2673-253XThe 2019 coronavirus (COVID-19) pandemic revealed the urgent need for the acceleration of vaccine development worldwide. Rapid vaccine development poses numerous risks for each category of vaccine technology. By using the Risklick artificial intelligence (AI), we estimated the risks associated with all types of COVID-19 vaccine during the early phase of vaccine development. We then performed a postmortem analysis of the probability and the impact matrix calculations by comparing the 2020 prognosis to the contemporary situation. We used the Risklick AI to evaluate the risks and their incidence associated with vaccine development in the early stage of the COVID-19 pandemic. Our analysis revealed the diversity of risks among vaccine technologies currently used by pharmaceutical companies providing vaccines. This analysis highlighted the current and future potential pitfalls connected to vaccine production during the COVID-19 pandemic. Hence, the Risklick AI appears as an essential tool in vaccine development for the treatment of COVID-19 in order to formally anticipate the risks, and increases the overall performance from the production to the distribution of the vaccines. The Risklick AI could, therefore, be extended to other fields of research and development and represent a novel opportunity in the calculation of production-associated risks.Quentin HaasQuentin HaasNikolay BorisovNikolay BorisovDavid Vicente AlvarezDavid Vicente AlvarezSohrab FerdowsiSohrab FerdowsiLeonhard von MeyennLeonhard von MeyennDouglas TeodoroDouglas TeodoroPoorya AminiPoorya AminiFrontiers Media S.A.articleartificial intelligencepharmacologyCOVID-19vaccinerisk analysisMedicineRPublic aspects of medicineRA1-1270Electronic computers. Computer scienceQA75.5-76.95ENFrontiers in Digital Health, Vol 3 (2021)
institution DOAJ
collection DOAJ
language EN
topic artificial intelligence
pharmacology
COVID-19
vaccine
risk analysis
Medicine
R
Public aspects of medicine
RA1-1270
Electronic computers. Computer science
QA75.5-76.95
spellingShingle artificial intelligence
pharmacology
COVID-19
vaccine
risk analysis
Medicine
R
Public aspects of medicine
RA1-1270
Electronic computers. Computer science
QA75.5-76.95
Quentin Haas
Quentin Haas
Nikolay Borisov
Nikolay Borisov
David Vicente Alvarez
David Vicente Alvarez
Sohrab Ferdowsi
Sohrab Ferdowsi
Leonhard von Meyenn
Leonhard von Meyenn
Douglas Teodoro
Douglas Teodoro
Poorya Amini
Poorya Amini
Vaccine Development in the Time of COVID-19: The Relevance of the Risklick AI to Assist in Risk Assessment and Optimize Performance
description The 2019 coronavirus (COVID-19) pandemic revealed the urgent need for the acceleration of vaccine development worldwide. Rapid vaccine development poses numerous risks for each category of vaccine technology. By using the Risklick artificial intelligence (AI), we estimated the risks associated with all types of COVID-19 vaccine during the early phase of vaccine development. We then performed a postmortem analysis of the probability and the impact matrix calculations by comparing the 2020 prognosis to the contemporary situation. We used the Risklick AI to evaluate the risks and their incidence associated with vaccine development in the early stage of the COVID-19 pandemic. Our analysis revealed the diversity of risks among vaccine technologies currently used by pharmaceutical companies providing vaccines. This analysis highlighted the current and future potential pitfalls connected to vaccine production during the COVID-19 pandemic. Hence, the Risklick AI appears as an essential tool in vaccine development for the treatment of COVID-19 in order to formally anticipate the risks, and increases the overall performance from the production to the distribution of the vaccines. The Risklick AI could, therefore, be extended to other fields of research and development and represent a novel opportunity in the calculation of production-associated risks.
format article
author Quentin Haas
Quentin Haas
Nikolay Borisov
Nikolay Borisov
David Vicente Alvarez
David Vicente Alvarez
Sohrab Ferdowsi
Sohrab Ferdowsi
Leonhard von Meyenn
Leonhard von Meyenn
Douglas Teodoro
Douglas Teodoro
Poorya Amini
Poorya Amini
author_facet Quentin Haas
Quentin Haas
Nikolay Borisov
Nikolay Borisov
David Vicente Alvarez
David Vicente Alvarez
Sohrab Ferdowsi
Sohrab Ferdowsi
Leonhard von Meyenn
Leonhard von Meyenn
Douglas Teodoro
Douglas Teodoro
Poorya Amini
Poorya Amini
author_sort Quentin Haas
title Vaccine Development in the Time of COVID-19: The Relevance of the Risklick AI to Assist in Risk Assessment and Optimize Performance
title_short Vaccine Development in the Time of COVID-19: The Relevance of the Risklick AI to Assist in Risk Assessment and Optimize Performance
title_full Vaccine Development in the Time of COVID-19: The Relevance of the Risklick AI to Assist in Risk Assessment and Optimize Performance
title_fullStr Vaccine Development in the Time of COVID-19: The Relevance of the Risklick AI to Assist in Risk Assessment and Optimize Performance
title_full_unstemmed Vaccine Development in the Time of COVID-19: The Relevance of the Risklick AI to Assist in Risk Assessment and Optimize Performance
title_sort vaccine development in the time of covid-19: the relevance of the risklick ai to assist in risk assessment and optimize performance
publisher Frontiers Media S.A.
publishDate 2021
url https://doaj.org/article/26473ecebba642e8bdcb15543e14aa70
work_keys_str_mv AT quentinhaas vaccinedevelopmentinthetimeofcovid19therelevanceoftherisklickaitoassistinriskassessmentandoptimizeperformance
AT quentinhaas vaccinedevelopmentinthetimeofcovid19therelevanceoftherisklickaitoassistinriskassessmentandoptimizeperformance
AT nikolayborisov vaccinedevelopmentinthetimeofcovid19therelevanceoftherisklickaitoassistinriskassessmentandoptimizeperformance
AT nikolayborisov vaccinedevelopmentinthetimeofcovid19therelevanceoftherisklickaitoassistinriskassessmentandoptimizeperformance
AT davidvicentealvarez vaccinedevelopmentinthetimeofcovid19therelevanceoftherisklickaitoassistinriskassessmentandoptimizeperformance
AT davidvicentealvarez vaccinedevelopmentinthetimeofcovid19therelevanceoftherisklickaitoassistinriskassessmentandoptimizeperformance
AT sohrabferdowsi vaccinedevelopmentinthetimeofcovid19therelevanceoftherisklickaitoassistinriskassessmentandoptimizeperformance
AT sohrabferdowsi vaccinedevelopmentinthetimeofcovid19therelevanceoftherisklickaitoassistinriskassessmentandoptimizeperformance
AT leonhardvonmeyenn vaccinedevelopmentinthetimeofcovid19therelevanceoftherisklickaitoassistinriskassessmentandoptimizeperformance
AT leonhardvonmeyenn vaccinedevelopmentinthetimeofcovid19therelevanceoftherisklickaitoassistinriskassessmentandoptimizeperformance
AT douglasteodoro vaccinedevelopmentinthetimeofcovid19therelevanceoftherisklickaitoassistinriskassessmentandoptimizeperformance
AT douglasteodoro vaccinedevelopmentinthetimeofcovid19therelevanceoftherisklickaitoassistinriskassessmentandoptimizeperformance
AT pooryaamini vaccinedevelopmentinthetimeofcovid19therelevanceoftherisklickaitoassistinriskassessmentandoptimizeperformance
AT pooryaamini vaccinedevelopmentinthetimeofcovid19therelevanceoftherisklickaitoassistinriskassessmentandoptimizeperformance
_version_ 1718405892150394880